Hosted on MSN9mon
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
This approval makes Lutathera the first therapy specifically reviewed ... that in adults for the approved dose. Lutathera (lutetium Lu 177 dotatate) is approved in the US for adults and children ...
pharmaphorum5d
FDA starts review of Lantheus’ generic Lutathera
Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera ... version of Lutathera (lutetium Lu 177 dotatate) to the US market.
Hosted on MSN11d
Three Key Takeaways from the 43rd Annual J.P. Morgan Healthcare Conference
Radiotherapy, China's biotech surge and AI's role in drug discovery are notable topics that emerged from conversations on the ...
ADVFN1mon
Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA
USAN: lutetium Lu 177 dotatate/INN: lutetium (177Lu) oxodotreotide, (Lutathera®) belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves ...
precisionmedicineonline7d
Novartis Posts Strong Q4 Sales of Kisqali, Pluvicto
During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.